NCT00631358View on ClinicalTrials.gov

Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention

PHASE4CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

February 28, 2009

Conditions
Sjogren's Syndrome
Interventions
DRUG

Maxidex

Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily

OTHER

No treatment

Healthy normal control group receiving no treatment

Trial Locations (2)

Unknown

Toronto, Toronto

Waterloo, Waterloo

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT00631358 - Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention | Biotech Hunter | Biotech Hunter